NCT05108623
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have progressed on Keytruda/pembrolizumab or Opdivo/nivolumab to be eligible for Part 2 of the study
Exclusions: Patients with untreated brain and/or leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT05108623
